Verrica Pharmaceuticals Inc. (VRCA) Stock Analysis & Investment Frameworks

Verrica Pharmaceuticals Inc. (VRCA) stock analysis on Invetso. Review Verrica Pharmaceuticals Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

Verrica Pharmaceuticals Inc. Company Overview

Verrica Pharmaceuticals Inc. Key Financial Metrics

About Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Verrica Pharmaceuticals Inc. Investment Frameworks

Invetso analyzes Verrica Pharmaceuticals Inc. (VRCA) across the following frameworks:

Explore More VRCA Research